| 14.275 0.135 (0.95%) | 10-24 14:57 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 17.32  |
1-year : | 20.23 |
| Resists | First : | 14.82 |
Second : | 17.32 |
| Pivot price | 13.85 |
|||
| Supports | First : | 13.76 |
Second : | 13.1 |
| MAs | MA(5) : | 14.22 |
MA(20) : | 13.96 |
| MA(100) : | 12.38 |
MA(250) : | 14.09 |
|
| MACD | MACD : | 0 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 68.4 |
D(3) : | 66.7 |
| RSI | RSI(14): 54.9 |
|||
| 52-week | High : | 21.47 | Low : | 9.19 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ EMBC ] has closed below upper band by 15.3%. Bollinger Bands are 42.1% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 2 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 14.39 - 14.48 | 14.48 - 14.56 |
| Low: | 13.78 - 13.87 | 13.87 - 13.95 |
| Close: | 14 - 14.15 | 14.15 - 14.28 |
Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety devices, as well as digital applications to assist people with managing their diabetes. The company primarily sells its products to wholesalers and distributors in the United States and internationally. Embecta Corp. was founded in 1924 and is based in Parsippany, New Jersey. Embecta Corp.(NasdaqGS:EMBC) operates independently of Becton, Dickinson and Company as of April 1, 2022.
Fri, 17 Oct 2025
Embecta Corp. (EMBC) Investor Outlook: Uncovering A 21.74% Potential Upside - DirectorsTalk Interviews
Fri, 03 Oct 2025
Embecta Corp. (EMBC) Investor Outlook: Unpacking The 16.88% Upside Potential - DirectorsTalk Interviews
Fri, 26 Sep 2025
Embecta Corp.'s (NASDAQ:EMBC) Intrinsic Value Is Potentially 99% Above Its Share Price - simplywall.st
Sun, 31 Aug 2025
Upgrading Embecta Due To Reorganization And Growth Initiatives (NASDAQ:EMBC) - Seeking Alpha
Tue, 26 Aug 2025
embecta to Participate in Investor Events - GlobeNewswire
Mon, 25 Aug 2025
Embecta Corp. (EMBC) Crossed Above the 200-Day Moving Average: What That Means for Investors - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | 58 (M) |
| Shares Float | 57 (M) |
| Held by Insiders | 0.4 (%) |
| Held by Institutions | 101.9 (%) |
| Shares Short | 2,490 (K) |
| Shares Short P.Month | 3,000 (K) |
| EPS | 1.41 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -11.45 |
| Profit Margin | 7.5 % |
| Operating Margin | 35.4 % |
| Return on Assets (ttm) | 3.7 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 8.3 % |
| Gross Profit (p.s.) | 11.94 |
| Sales Per Share | 18.8 |
| EBITDA (p.s.) | 1.89 |
| Qtrly Earnings Growth | 211.1 % |
| Operating Cash Flow | 134 (M) |
| Levered Free Cash Flow | 11 (M) |
| PE Ratio | 10.07 |
| PEG Ratio | 0 |
| Price to Book value | -1.25 |
| Price to Sales | 0.76 |
| Price to Cash Flow | 6.23 |
| Dividend | 0.15 |
| Forward Dividend | 0 |
| Dividend Yield | 1% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|